Citicoline (CDP-Choline): Cognizin vs the Null Stroke Trial

By Erin Rose · Updated July 18, 2026 · Methodology

Educational overview — not medical advice. Citicoline is used clinically abroad for stroke and cognitive-impairment indications; nothing here should be read as a diagnosis or treatment recommendation. This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

As an Amazon Associate we earn from qualifying purchases. On best citicoline, products are ranked by cost per mg, never by commissions.

Start here

What citicoline is, and the two-pathway mechanism

Citicoline (cytidine-5'-diphosphocholine, or CDP-choline) is a nootropic compound that yields two usable building blocks when the body absorbs and metabolizes it: choline, the same raw material alpha-GPC delivers, and cytidine, which the body can convert to uridine — both involved in neuronal membrane synthesis and neurotransmitter production. That two-pathway mechanism is real and distinguishes citicoline from straight choline donors. What it doesn't automatically prove is a reliable cognitive benefit for a healthy adult taking a retail capsule — and that's the honesty gap this cluster is built to close. Citicoline is available over-the-counter as a dietary supplement in the US, but it's also used as a prescription-strength clinical agent for stroke and cognitive-impairment indications in Italy, Spain, Japan, and other countries — real-world clinical use that is not, by itself, proof of efficacy from a controlled trial.

The healthy-adult evidence: two trials, both Cognizin-funded

The modest attention/memory signal in near-healthy populations comes almost entirely from two PubMed-indexed trials, both using Cognizin® citicoline (Kyowa Hakko's branded raw material) and both funded by or co-authored with Kyowa Hakko employees — disclose this every time either is cited. McGlade et al. 2019 randomized 75 healthy adolescent males to 250mg or 500mg Cognizin/day or placebo for 28 days, finding improved attention (p=0.02) and increased psychomotor speed (p=0.03) — a single-sex, adolescent population, not general healthy adults. Nakazaki et al. 2021 randomized 100 adults aged 50-85 with age-associated memory impairment (not a fully "healthy" sample) to 500mg Cognizin/day or placebo for 12 weeks, finding a significantly greater improvement on a secondary episodic-memory outcome (p=0.0025). Both are real, peer-reviewed, indexed trials — and both are industry-funded, modest in effect size, and short in duration (28 days, 12 weeks). See the full scoping on focus, attention & memory.

The essential counterweight: ICTUS, the null stroke trial

Here is the fact that belongs at the top of any honest citicoline page: the largest, best-designed clinical trial ever run on citicoline — ICTUS (Dávalos et al. 2012, The Lancet) — randomized 2,298 patients with moderate-to-severe acute ischemic stroke to citicoline (1,000mg IV every 12 hours for 3 days, then 2×500mg oral every 12 hours through 6 weeks — 2,000mg/day in the oral phase) or placebo. Global recovery at 90 days was not significantly different between groups (OR 1.03, 95% CI 0.86-1.25, p=0.364). This is an independent, academic, international multicenter trial — not industry-funded the way the cognition trials above are — and it is the single most rigorous test citicoline has ever faced for its most clinically important claimed use. Citicoline's widespread clinical use for stroke and cognitive-impairment indications abroad is real-world practice, not proof of efficacy from the largest controlled trial. State both facts side by side, never one without the other.

The buying question: Cognizin vs. generic

Cognizin® and generic "CDP-Choline"/"citicoline sodium" are very likely the same underlying molecule — this is not a "generic is fake" story the way some other ingredient categories legitimately are. The honest differentiator is chain-of-custody: Cognizin is the specific branded raw material actually used in the McGlade and Nakazaki trials, and its use is disclosed on-label; generics are probably chemically equivalent citicoline sodium sold without that trial link. Ranked strictly by cost per mg, the cheapest product tracked on this site is actually Life Extension's Cognizin-branded pick — not a generic, which upends the usual "generic is always cheaper" pattern. Healthy Origins's Cognizin product has the lowest total sticker price ($13.99) if you just want to try Cognizin at minimal commitment, though it costs more per mg. See the full ranking on best citicoline.

Frequently asked questions

Related guides

• Alpha-GPC — the other choline-donor nootropic, with its own 2021 observational stroke-risk association
• Phosphatidylserine — another cognition supplement where the FDA-claim trials used a discontinued raw material
• NMN — another structural twin: a real biomarker rising alongside a rigorous null clinical result
• Omega-3 — the site's brain-health ingredient with the strongest triglyceride-lowering evidence

Sources